Therapeutic peptides from IK cytokine ameliorate rheumatoid arthritis through the suppression of macrophage activation as well as T<sub>H</sub>1 and T<sub>H</sub>17 cell differentiation — ASN Events
  1. Schedule
  2. Poster Session 2
  3. Therapeutic peptides from IK cytokine ameliorate rheumatoid arthritis through the suppression of macrophage activation as well as TH1 and TH17 cell differentiation

Therapeutic peptides from IK cytokine ameliorate rheumatoid arthritis through the suppression of macrophage activation as well as TH1 and TH17 cell differentiation (#142)

Hye-Lim Park 1 , Jun-Ki Min 2 , Sang-Myeong Lee 3 , Mi-La Cho 2 , Su-Jin Moon 2 , Inki Kim 4 , Dong-Hee Lee 5 , Sooho Park 1 , Hyun-Jung Jeon 1 , Sang-Yeon Lee 1 , Seul-Gi Choi 1 , Jae-Hwan Nam 1
  1. Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
  2. The Rheumatism Research Center, Catholic Research Institute of Medical Science, Seoul, South Korea
  3. Biotechnology, Chonbuk National University, Iksan, Jeollabuk-do , South Korea
  4. Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea
  5. Biomaterials Research Center, Cellinbio, Suwon-si, Gyeonggi-do, South Korea
The pathogenesis of inflammatory autoimmune rheumatoid arthritis (RA) is driven by the activation of macrophages and the development of pathogenic interferon-g (IFN-g)- and interleukin-17 (IL-17)-producing CD4+ T cells (TH1 and TH17 cells). Here, we found that truncated IK (tIK) cytokine, an inhibitor of IFN-g-induced MHC class II expression, ameliorated RA in a mouse model and was associated with decreases in joint swelling, bone destruction, and incidence of RA. Notably, the potential phosphorylation sites on tIK cytokine were identified. Interestingly, tIK active peptides showed an immune regulatory function through inhibition of pathogenic macrophage activation and suppression of TH1 and TH17 cell differentiation. Moreover, in a mouse model of RA, administration of tIK active peptides potently suppressed the progression of inflammatory arthritis, and this suppression correlated significantly with reduced incidence and severity of arthritis. These findings suggest that tIK cytokine may be an effective immunotherapeutic approach for RA through its immune-regulating actions.